The mRNA Writing On The Wall, GSK Expands CureVac Alliance Into Next-Gen COVID-19 Vaccines

Includes 100m Dose Boost To CureVac's COVID-19 Manufacturing

 
• By Andrew McConaghie

After major setbacks to its existing COVID-19 vaccine platform, GSK is expanding its presence in mRNA, which increasingly looks to be the future.  

GSK HQ
GSK is one of the world's biggest vaccines companies, but is not a leader in the fast-emerging mRNA field.

More from Business

More from Scrip